Stockscreener 앱 받기
10.31
0.68%
0.07
Omeros Corporation 주식(OMER)의 최신 뉴스
Wellington Management Group LLP Invests $305,000 in Omeros Co. (NASDAQ:OMER) - MarketBeat
Needham & Company LLC Reiterates Hold Rating for Omeros (NASDAQ:OMER) - Defense World
Omeros Corporation Announces Positive Results for Narsoplimab in Treating Thrombotic MicroangiopathyOn December 19, 2024, Omeros Corporation (NASDAQ: OMER) revealed the outcomes of a primary statistical analysis involving narsoplimab, the comp - Defense World
Omeros' (OMER) Hold Rating Reaffirmed at Needham & Company LLC - MarketBeat
BNP Paribas Financial Markets Buys 7,016 Shares of Omeros Co. (NASDAQ:OMER) - Defense World
Omeros (NASDAQ:OMER) Reaches New 12-Month HighStill a Buy? - MarketBeat
Stock Of The Day / 12.19.24 / OMER for NASDAQ:OMER by AlexX31 - TradingView
Top Midday Gainers - Marketscreener.com
Omeros jumps as lead drug succeeds in pivotal trial for blood transplant patients - MSN
Omeros Antibody Improves Overall Survival In Rare Complication After Stem Cell Transplant, Stock Surges - Benzinga
Omeros (NASDAQ:OMER) Shares Gap UpShould You Buy? - MarketBeat
Omeros Stock Gains 52% On Successful Trial Results - MarketWatch
Omeros antibody improves overall survival by 68% in rare condition, new analysis finds - Fierce Biotech
Omeros stock soars to 52-week high, hits $12.65 - Investing.com
Omeros Reports Narsoplimab TA-TMA Trial Success; Stock Surges - Yahoo Finance
Omeros stock surges on positive survival data for narsoplimab - Investing.com
Omeros stock jumps after trial outcome (OMER:NASDAQ) - Seeking Alpha
Omeros reports survival benefit with narsoplimab in TA-TMA - Investing.com
Omeros announces narsoplimab trial meets primary endpoint - TipRanks
Omeros’ Narsoplimab Meets its Pivotal Trial Primary Endpoint – Statistical Analysis Shows Survival Superiority Over External Control in Patients with TA-TMA - Business Wire
Omeros (STU:3O8) Operating Income : €-159.24 Mil (TTM As of Sep. 2024) - GuruFocus.com
Omeros (STU:3O8) GF Score : 50/100 (As of Dec. 18, 2024) - GuruFocus.com
Omeros Co. (NASDAQ:OMER) Short Interest Down 16.9% in November - MarketBeat
Omeros Corporation: Investment Opportunity Finely Poised As The Market Waits For Key Updates - Seeking Alpha
Omeros Corporation (OMER) Stock Drops Amid Financial Report Conc - GuruFocus.com
Omeros Corp (OMER): Profit-Taking Time Amid ASH Presentations and Financial Challenges - MSN
Omeros Corporation Announces Presentation of Positive Zaltenibart Data at ASH Annual Meeting - BioSpace
Omeros reports progress on PNH treatment zaltenibart - Investing.com
Omeros reports progress on PNH treatment zaltenibart By Investing.com - Investing.com UK
Omeros (NASDAQ:OMER) Stock Price Up 7.8%What's Next? - MarketBeat
Omeros stock soars to 52-week high, hits $12.55 By Investing.com - Investing.com Australia
Omeros stock soars to 52-week high, hits $12.55 - Investing.com
Omeros Corporation (OMER) Stock Surges Amidst Biotech Sector Gai - GuruFocus.com
Omeros Corp (OMER) Stock Surges Amid Biotech Sector Activity - GuruFocus.com
Omeros Corporation Announces Upcoming Presentations at ASH Annual Meeting - The Bakersfield Californian
(OMER) Trading Advice - Stock Traders Daily
Omeros Corp (OMER) Stock Surges Amidst Biotech Sector Activity - GuruFocus.com
Omeros (NASDAQ:OMER) Hits New 12-Month HighHere's Why - MarketBeat
Omeros Updates Progress on Narsoplimab Biologics License Resubmission; Stock up Over 30% on News - Yahoo Finance
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
Omeros stock soars to 52-week high, hits $7.53 By Investing.com - Investing.com Australia
Omeros nears resubmission of narsoplimab BLA By Investing.com - Investing.com South Africa
Omeros nears resubmission of narsoplimab BLA - Investing.com India
Omeros stock soars to 52-week high, hits $7.53 - Investing.com
Omeros Corporation Provides Update on Progress Toward BLA Resubmission - Business Wire
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.47% - MSN
StockNews.com Upgrades Omeros (NASDAQ:OMER) to Hold - MarketBeat
Omeros (NASDAQ:OMER) Upgraded at StockNews.com - Defense World
Long Term Trading Analysis for (OMER) - Stock Traders Daily
IgA Nephropathy Drugs Market: Driving Rapid Expansion with - openPR
2.88%
2.65%
자본화:
|
볼륨(24시간):